SecBot SecBot
8-K ·Filed Aug 3, 2026

KRYS

Krystal Biotech, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001711279-26-000058
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The slight revenue miss vs. consensus ($119.2M vs. $121.0M) may cause some near-term pressure, but the EPS beat and strong operational metrics (24% revenue growth, 95% gross margin, $1.1B cash) support the bull case. The key catalysts are the KB803 top-line readout in 4Q 2026 and the KB407 CF registrational study design alignment with FDA, also expected in 4Q 2026. Traders should monitor for any analyst revisions following the revenue miss and watch for the upcoming data readouts as the primary drivers.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$312.57
T+0 close · Aug 3, 2026 · via day close
Latest settled
+0.92%
T+60 · $315.43
Vs SPY
−0.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $312.57entry
  2. T+1 · 4mo ago +3.90%α +2.10% · $324.77
  3. T+5 · 3mo ago +6.08%α +4.06% · $331.59
  4. T+20 · 3mo ago +14.97%α +13.73% · $359.36
  5. T+60 · 21d ago +0.92%α −0.87% · $315.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M consensus, with GAAP diluted EPS of $1.79 vs. the Street consensus of $1.70, representing a beat. The company maintained its FY 2026 non-GAAP R&D and SG&A expense guidance of $175-195M. The quarter showed strong commercial execution with 730+ reimbursement approvals and 640+ prescribers, while the pipeline advanced with multiple registrational readouts expected in 2H 2026, including top-line data for KB803 in 4Q 2026. The slight revenue miss relative to consensus tempers the otherwise positive operational update, resulting in a neutral-to-modestly-bullish read.

Key Financial Metrics

EPS
$1.79
est $1.70 · +5.3%
Revenue
$119.2M
est $121.0M · -1.5% · +24.1% YoY
Rating
beat
Gross Margin
94.6%

Key Facts

  • Q2 2026 VYJUVEK global revenue of $119.2M, up 24% YoY from $96.0M
  • GAAP diluted EPS of $1.79, beating the $1.70 Street consensus
  • Revenue of $119.2M slightly below the $121.0M consensus estimate
  • Cash and investments of $1.1B, up from $955.9M at year-end 2025
  • Over 730 reimbursement approvals and 640+ unique prescribers for VYJUVEK
  • FY 2026 non-GAAP R&D and SG&A expense guidance maintained at $175-195M
  • KB803 IOLITE study fully enrolled, top-line data expected in 4Q 2026
  • KB801 EMERALD-1 enrollment on track for completion before year-end
  • KB407 CF study interim results expected before year-end
  • VYJUVEK approved in the UK; launches in Spain and Italy expected before year-end

Financial Impact

Q2 2026 product revenue of $119.2M (+24% YoY); GAAP net income of $54.8M ($1.79 diluted EPS) vs. $38.3M ($1.29) in Q2 2025

revenueepscash

Risk Factors

  • Revenue slightly missed consensus estimates, which could lead to near-term analyst downgrades
  • European pricing negotiations in Germany and France remain ongoing with uncertain timelines
  • Pipeline readouts (KB803, KB801, KB407) are binary events with potential for negative data
  • Dependence on VYJUVEK as the sole commercial product; pipeline candidates are still in development

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001711279-26-000058
Document: krys-20260803.htm0001711279-26-000058
Document: 0001711279-26-000058-index-headers.html0001711279-26-000058
Document: 0001711279-26-000058-index.html0001711279-26-000058
Document: 0001711279-26-000058.txt0001711279-26-000058
8-K Data (Synthetic)0001711279-26-000058

Track record

18 reports on KRYS

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
  3. Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
  4. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  5. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  6. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  7. Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  8. Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
  9. Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
  10. Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026